An observational study in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Assiut University · Observational
this study aims to investigate the prevalence of hematological abnormalities among patients with clinically diagnosed MASLD, evaluate their clinical correlates, and examine their association with non-invasive fibrosis scores. The findings may improve risk stratification and facilitate early identification of patients who require closer monitoring or further hepatological assessment.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent chronic liver diseases worldwide, with its burden increasing in parallel with obesity, type 2 diabetes mellitus, and metabolic syndrome. Progressive forms of MASLD may lead to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related complications. Beyond hepatic injury, MASLD is increasingly recognized as a multisystem disorder associated with extrahepatic manifestations.
Hematological abnormalities, including anemia, neutropenia, and platelet abnormalities, have been reported in patients with chronic liver disease. These abnormalities may be related to chronic inflammation, hypersplenism, nutritional deficiencies, bone marrow suppression, or impaired thrombopoietin production. Platelet count is also incorporated into commonly used non-invasive fibrosis scores, including the Fibrosis-4 (FIB-4) index and the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI).
Although hematological parameters are routinely available through complete blood count (CBC) testing, the prevalence and clinical significance of CBC abnormalities among patients with clinically diagnosed MASLD remain insufficiently characterized. Evaluating these abnormalities may provide additional information for clinical risk stratification and identification of patients who may require further hepatological assessment.
Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
El-Raghy Hospital patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
• To determine the difference in prevalence of thrombocytopenia between cases and controls
To determine the difference in prevalence of thrombocytopenia between patients with clinically diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) and control participants.
Time frame: Baseline (at the index CBC assessment corresponding to MASLD diagnosis for cases and the corresponding index CBC assessment for controls).
· To determine the difference in prevalence of other hematological abnormalities, including anemia, neutropenia, thrombocytosis, and any complete blood count (CBC) abnormality
Time frame: Baseline (at the index CBC assessment corresponding to MASLD diagnosis for cases and the corresponding index CBC assessment for controls)
· To assess the association between hematological abnormalities and demographic and clinical characteristics
Time frame: Baseline (at the index assessment corresponding to the CBC assessment for cases and the corresponding index assessment for controls).
· To evaluate the relationship between CBC abnormalities and non-invasive liver fibrosis scores, including the Fibrosis-4 Index (FIB-4) and the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI)
Time frame: Baseline (using laboratory data corresponding to the index CBC assessment for cases and the corresponding index assessment for controls).
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.